InsiderTrades.com logo
Scott Moomaw net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Scott Moomaw Biography and Net Worth

Chief Commercial Officer of Liquidia

Scott Moomaw, MBA joined Liquidia in 2020 where he serves as Chief Commercial Officer (CCO). Scott is a seasoned leader in biopharmaceuticals with extensive experience launching products and developing commercial strategies and organizations. He joined Liquidia from RareGen, which he co-founded, to commercialize Treprostinil Injection for pulmonary arterial hypertension (PAH). Prior to RareGen, Scott was Vice President of Marketing at Opko Health and United Therapeutics where he was responsible for Remodulin® (parenteral treprostinil), Tyvaso® (inhaled treprostinil) and Orenitram® (oral treprostinil) for PAH. Scott also held a variety of sales and marketing roles of increasing responsibility at Eli Lilly for over 10 years. He holds a Master of Business Administration from the University of Michigan and a Bachelor of Science from Miami University.

What is Scott Moomaw's net worth?

The estimated net worth of Scott Moomaw is at least $2.33 million as of December 2nd, 2024. Mr. Moomaw owns 154,127 shares of Liquidia stock worth more than $2,330,400 as of March 24th. This net worth evaluation does not reflect any other investments that Mr. Moomaw may own. Learn More about Scott Moomaw's net worth.

How old is Scott Moomaw?

Mr. Moomaw is currently 53 years old. There are 5 older executives and no younger executives at Liquidia. The oldest executive at Liquidia is Dr. Roger A. Jeffs Ph.D., CEO & Director, who is 62 years old. Learn More on Scott Moomaw's age.

How do I contact Scott Moomaw?

The corporate mailing address for Mr. Moomaw and other Liquidia executives is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. Liquidia can also be reached via phone at (919) 328-4400 and via email at ir@liquidia.com. Learn More on Scott Moomaw's contact information.

Has Scott Moomaw been buying or selling shares of Liquidia?

Scott Moomaw has not been actively trading shares of Liquidia during the last quarter. Most recently, Scott Moomaw sold 546 shares of the business's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $11.51, for a transaction totalling $6,284.46. Following the completion of the sale, the insider now directly owns 154,127 shares of the company's stock, valued at $1,774,001.77. Learn More on Scott Moomaw's trading history.

Who are Liquidia's active insiders?

Liquidia's insider roster includes Jason Adair (Chief Business Officer), Arthur Kirsch (Director), Paul Manning (Director), Scott Moomaw (Chief Commercial Officer), and Russell Schundler (General Counsel). Learn More on Liquidia's active insiders.

Are insiders buying or selling shares of Liquidia?

In the last year, Liquidia insiders bought shares 1 times. They purchased a total of 150,000 shares worth more than $1,426,500.00. In the last year, insiders at the sold shares 31 times. They sold a total of 133,327 shares worth more than $1,616,512.79. The most recent insider tranaction occured on January, 27th when insider Jason Adair sold 445 shares worth more than $6,319.00. Insiders at Liquidia own 30.1% of the company. Learn More about insider trades at Liquidia.

Information on this page was last updated on 1/27/2025.

Scott Moomaw Insider Trading History at Liquidia

See Full Table

Scott Moomaw Buying and Selling Activity at Liquidia

This chart shows Scott Moomaw's buying and selling at Liquidia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10k$0$10kTotal Insider BuyingTotal Insider Selling

Liquidia Company Overview

Liquidia logo
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Read More

Today's Range

Now: $15.65
Low: $15.08
High: $15.86

50 Day Range

MA: $14.79
Low: $11.36
High: $16.52

2 Week Range

Now: $15.65
Low: $8.26
High: $16.92

Volume

527,747 shs

Average Volume

933,980 shs

Market Capitalization

$1.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07